瑞舒伐他汀治疗冠心病的效果及对患者血清IL-17、TGF-β1、sCD40L水平的影响  

Curative effect of rosuvastatin on coronary heart disease and its influence on serum IL-17,TGF-β1 and sCD40L level

作　　者：宋欢欢[1] 武鑫玲[1] 张宁[1] 金玉[1] 赵少华[1] Song Huanhuan;Wu Xinling;Zhang Ning;Jin Yu;Zhao Shaohua(Department of Cardiology,Zhengzhou People’s Hospital,Zhengzhou 450000,China)

机构地区：[1]郑州人民医院心内科,郑州450000

出　　处：《中国实用医刊》2022年第8期94-97,共4页Chinese Journal of Practical Medicine

摘　　要：目的探讨瑞舒伐他汀治疗冠心病(CHD)的效果及对患者血清白细胞介素-17(IL-17)、转化生长因子-β1(TGF-β1)、可溶性CD40配体(sCD40L)水平的影响。方法抽取郑州人民医院2019年1月至2020年12月收治的90例CHD患者,按随机数字表法分为对照组与观察组,每组45例。对照组给予阿托伐他汀治疗,观察组给予瑞舒伐他汀治疗,观察两组治疗效果,治疗前后血脂水平、血清炎症因子水平及血管内皮功能的变化。结果观察组治疗总有效率(93.33%,42/47)高于对照组(86.67%,39/47),P<0.05。治疗3个月后,两组总胆固醇、低密度脂蛋白胆固醇水平均低于治疗前(P<0.05),但组间比较差异未见统计学意义(P>0.05);两组高密度脂蛋白胆固醇水平均较治疗前升高,且观察组水平高于对照组(P<0.05)。治疗3个月后,两组血清IL-17、TGF-β1、sCD40L水平均低于治疗前,且观察组血清IL-17、TGF-β1、sCD40L水平低于对照组(P<0.05)。治疗3个月后,两组血清内皮素-1、血管紧张素Ⅱ水平低于治疗前,血管内皮生长因子水平高于治疗前(P<0.05),但组间比较差异未见统计学意义(P>0.05)。结论瑞舒伐他汀治疗CHD的临床效果明显,且具有一定的调脂、抗炎作用,可有效降低患者血清中IL-17、TGF-β1及sCD40L水平。Objective To analyze the efficacy of rosuvastatin in the treatment of coronary heart disease(CHD),and its influence on levels of serum interleukin-17(IL-17),transforming growth factor-β1(TGF-β1)and soluble CD40 ligand(sCD40L).Methods Ninety patients with CHD treated in Zhengzhou People’s Hospital from January 2019 to December 2020 were selected.And they were divided into control group and observation group by random number table method,with 45 cases in each group.The control group was treated with atorvastatin,and the observation group was treated with rosuvastatin.The therapeutic effect,blood lipid level,serum inflammatory factor level and vascular endothelial function of the two groups were observed before and after treatment.Result The total effective rate of the observation group(93.33%,42/47)was higher than that in the control group(86.67%,39/47),P<0.05.After 3 months of treatment,the levels of total cholesterol(TG)and low-density lipoprotein cholesterol(LDL-C)were significantly reduced in the two groups(P<0.05),but there was no significant differences between the two groups(P>0.05).The levels of high-density lipoprotein cholesterol(HDL-C)in the two groups was significantly higher than those before treatment,and the HDL-C level in the observation group was higher than that in the control group(P<0.05).After 3 months of treatment,serum IL-17,TGF-β1,SCD40L levels in the two groups were lower than those before treatment,and serum levels of IL-17,TGF-β1,SCD40L in the observation group were lower than those in the control group(P<0.05).After 3 months of treatment,the serum levels of endothelin-1 and angiotensin II in the two groups were significantly decreased,and the level of vascular endothelial growth factor increased,compared with those before treatment(P<0.05),but there was no significant difference between the two groups(P>0.05).Conclusions Rosuvastatin has significant clinical effects in the treatment of CHD.And it has certain lipid-lowering and anti-inflammatory effects,and it can effectively reduce

关 键 词：冠心病 瑞舒伐他汀 白细胞介素-7 转化生长因子-Β1 可溶性CD40配体 

分 类 号：R541.4[医药卫生—心血管疾病]